<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903548</url>
  </required_header>
  <id_info>
    <org_study_id>017.HEP.2020.D</org_study_id>
    <nct_id>NCT04903548</nct_id>
  </id_info>
  <brief_title>Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres</brief_title>
  <official_title>Evaluating the Effects of Segmental/Super Selective Treatment Utilizing Flex-dosing in Treating Unresectable HCC With Y90 SIR-Spheres</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this research study is to evaluate outcomes associated with&#xD;
      flex-dosing in Y90 SIR-Sphere administration in a prospective cohort of unresectable HCC&#xD;
      patients eligible for segmental/super selective treatment at Methodist Dallas Medical Center&#xD;
      (MDMC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of this research study is to evaluate outcomes associated with&#xD;
      flex-dosing in Y90 SIR-Sphere administration in a prospective cohort of unresectable HCC&#xD;
      patients eligible for segmental/super selective treatment at Methodist Dallas Medical Center&#xD;
      (MDMC).&#xD;
&#xD;
      This study will enable physicians to be more precise in administering the correct&#xD;
      radio-embolic dose, which will improve safety and efficacy of treatment while maintaining&#xD;
      optimal dosing for tumor side effects. This study could potentially identify tumors earlier&#xD;
      in the course of disease progression, which may result in more efficacious treatment and&#xD;
      quality of life for patients. Earlier diagnosis and treatment may result in decreased costs.&#xD;
&#xD;
      This is a prospective cohort registry study. The prospective study cases will include all&#xD;
      eligible Y90 patients, who meet the inclusion criteria who are treated beginning in May 2020&#xD;
      to May 2022. Follow-up of patients included in study will continue as needed in order to&#xD;
      evaluate survival outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient demographics</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>Patient demographics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volumes for liver to be treated</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>liver volume prior to treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lobe/segment to be treated</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>treatment location</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor volume</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>volume of tumor prior to treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung Shunt</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>Lung shunt presence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor to normal ratio Tumor to Normal ratio prior to greatment</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>T:N</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of liver disease</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>Child-Pugh score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver synthetic function</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>ALBI (albumin-bilirubin) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>using modified response evaluation criteria in solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>Progression-free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital-based charges/costs</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>Hospital-based charges/costs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver function tests</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>Measurement of Alanine transaminase (ALT), Aspartate transaminase (AST), Alkaline phosphatase (ALP), Albumin and total protein, Bilirubin, Prothrombin time (PT), L-lactate dehydrogenase (LD), Gamma-glutamyltransferase (GGT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SPECT CT</measure>
    <time_frame>May 2020 - 2022</time_frame>
    <description>for missed Y90 administrations or extrahepatic Y90</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SIRT with Y-90 resin microspheres</intervention_name>
    <description>Selective internal radiation therapy (SIRT) with Y-90 resin microspheres (Y-90 resin SIRT) is an intra-arterial, catheter-based locoregional therapy that has been used to treat patients with unresectable HCC</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients diagnosed with unresectable HCC in two of fewer hepatic segments at MDMC who&#xD;
        undergo at least one SIRT procedure with Y-90 resin microspheres&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  All patients diagnosed with unresectable HCC in two of fewer hepatic segments at MDMC&#xD;
             who undergo at least one SIRT procedure with Y-90 resin microspheres (SIR-SpheresÂ®,&#xD;
             Sirtex Medical Limited, Sydney, Australia) will be included in data capture. HCC is&#xD;
             considered unresectable if it is multifocal or bilobar, or if the patient has&#xD;
             malignant portal vein thrombosis, portal hypertension, or decompensated liver disease&#xD;
             (Child-Pugh B or C).&#xD;
&#xD;
          -  Eligible cases for inclusion are those that would have undergone Y-90 resin SIRT and&#xD;
             had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;&#xD;
             platelets &gt;60,000; creatinine &lt;2 mg/dL; bilirubin &lt;2 mg/dL; and international&#xD;
             normalized ratio (INR) &lt;1.2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects that do not meet the inclusion criteria&#xD;
&#xD;
          -  Patients are not eligible for SIRT if they had any extrahepatic disease;&#xD;
             contraindication to hepatic artery catheterization such as vascular abnormalities,&#xD;
             bleeding diathesis, allergy to contrast dye, concurrent malignancy, refractory&#xD;
             ascites, previous external beam radiation, or evidence of any uncorrectable flow to&#xD;
             the gastrointestinal tract; or greater than 30 Gy of radiation estimated to be&#xD;
             delivered to the lung based on angiography or Tc-99 microaggregated albumin scan&#xD;
             (shunt fraction of 20% or greater).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parvez Mantry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Crystee Cooper, DHEd</last_name>
    <phone>214-947-1280</phone>
    <email>ClinicalResearch@mhd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zaid Haddadin, MS</last_name>
    <phone>214-947-4604</phone>
    <email>ClinicalResearch@mhd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parvez Mantry, MD</last_name>
      <email>ClinicalResearch@mhd.com</email>
    </contact>
    <contact_backup>
      <last_name>Elaina Vivian, MPH</last_name>
      <phone>214-933-6611</phone>
      <email>ClinicalResearch@mhd.com</email>
    </contact_backup>
    <investigator>
      <last_name>Islam Shahin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandru Bageac, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

